High blood pressure (hypertension) and congestive heart failure (CHF) drugs that contain the drug valsartan were recalled recently, but the recall was just expanded August 8, 2018. In this latest update, the Food and Drug Administration (FDA) says it expanded the list of products affected under the recall and even some valsartan-containing … [Read more...]
Heart Medication Recalled Due to Contamination and Cancer Risk
On July 13, 2018, The U.S. Food and Drug Administration (FDA) announced a voluntary recall of certain medications containing valsartan. Valsartan is the active ingredient in some drugs used to treat high blood pressure and heart failure. Valsartan supplied to the drug manufacturers, by a specific third-party, has been found to be contaminated with … [Read more...]
Tasigna – Atherosclerosis
Tasigna (nilotinib) is a chemotherapy drug originally approved to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Tasigna can have serious and life-threatening side effects, including the development of atherosclerosis. When the drug was approved by the U.S. Food and Drug Administration (FDA) in 2007, it carried … [Read more...]
FDA Will ‘Take Another Look’ at Controversial Parkinson’s Drug
When, two years ago, the FDA reviewed the Parkinson’s drug, Nuplazid, lead medical reviewer Dr. Paul Andreason issued grave warnings about the potential risks. During the review process, he observed that those taking the actual medication were suffering extreme side-effects (including death) twice as much as those taking placebos. In addition, he … [Read more...]
Nuplazid Deaths
Nuplazid (pimavanserin) is a new-generation Parkinson’s disease drug, introduced in April 2016. The U.S. Food and Drug Administration (FDA) has already received at least 5,735 adverse event reports including 712 deaths linked to Nuplazid in the short time that it has been on the market. The drug is made by Acadia Pharmaceuticals and is an atypical … [Read more...]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 39
- Next Page »
Recent Comments